Corona Remedies IPO Opens: Key Details & Strong GMP
Corona Remedies IPO subscription starts Dec 8. Price band ₹1008-1062, aims to raise ₹655 cr. Grey market premium signals strong investor interest. Details inside.
Corona Remedies IPO subscription starts Dec 8. Price band ₹1008-1062, aims to raise ₹655 cr. Grey market premium signals strong investor interest. Details inside.
Corona Remedies' ₹655 crore IPO opens today. With a price band of ₹1,008-₹1,062 and a strong GMP, analysts give a 'Subscribe for long term' rating. Key dates and details inside.
Odisha's new Pharma & Medtech Policy 2025 aims to make the state a strategic hub for healthcare manufacturing. The policy includes plans for dedicated industrial parks and a roadmap aligned with India's 2047 vision. Read more.
Himachal Pradesh's pharmaceutical hub is in turmoil as 38 firms lose WHO-GMP certification, raising serious quality concerns. Discover the causes and impact.
Nivin Pauly's OTT debut 'Pharma' trailer reveals a medical rep exposing dangerous drugs. The series premieres on JioCinema December 19 in 7 languages. Read more.
Hyderabad's Laurus Labs plans aggressive CDMO growth, targeting 50% of revenue in five years. CEO Dr. Satyanarayana Chava reveals strategy focusing on cell & gene therapy and global expansion. Read more.
A woman found lost at Nagpur station, battling psychosis, recovers with mental hospital aid, wins back ₹20 lakh property from fraudsters, and now awaits motherhood in Visakhapatnam. A story of resilience.
Granules India's US subsidiary, Granules Consumer Health LLC, successfully cleared a USFDA GMP inspection with zero observations. This marks a significant achievement for the Hyderabad-based pharma major's OTC product operations in America.
Corona Remedies IPO opens Dec 8, 2025, to raise ₹655.37 crore. Check price band, GMP, financials, and key dates for this pharma company's public issue.
Indian stock markets opened strong on December 3, 2025, with Nifty crossing 25,400. Key stocks like TCS and Sun Pharma in focus. Read for full analysis and trading cues.
LinkedIn's 2025 ranking reveals the 50 best US colleges for sustained career growth. Discover which universities, including Princeton and Duke, best prepare students for the modern workforce.
Wockhardt's share price surged over 6% after the USFDA accepted its New Drug Application for Zaynich, a novel antibiotic. Discover the details and market impact.
Sun Pharma introduces its global biologic Ilumya for moderate-to-severe plaque psoriasis in India. Backed by Phase-3 data, it offers long-lasting clearance with a strong safety profile. Learn more about this targeted therapy.
Author Kiran Manral's new book 'The Gamechangers' spotlights Indian women entrepreneurs who are rewriting the rules of business with purpose and empathy, not just hustle. Discover their inspiring stories.
OpenAI CEO Sam Altman reveals 5 powerful success principles for massive wealth and impact. Learn how compounding, self-belief and smart risks can transform your career.
Indian API manufacturers are shifting to high-value contract development, targeting $22-25 billion market by 2035 as global pharma diversifies from China. Read about the growth trajectory.
Speciality chemical makers supplying pharma CDMOs post 7% sales growth, outpacing non-pharma peers. Strong margins and global shifts fuel this resilient sector. Read more.
November 2025 witnessed 9 IPOs with 12 listings. Groww leads with 58.85% gains while experts warn of investor fatigue and unrealistic valuations. Read full analysis.
Sudeep Pharma shares surged 33.78% in market debut, exceeding expectations. Analysts advise partial profit booking while maintaining long-term optimism. Read expert views on buy/sell strategy.
Sudeep Pharma shares surged 23% in stock market debut today, outperforming grey market expectations. The ₹895-crore IPO was subscribed 93.71 times. Read full analysis.
Sudeep Pharma makes its stock market debut today. With a GMP of ₹121, the IPO is set for 20% listing gains after a blockbuster 93.72 times subscription. Get all the live details.
Sudeep Pharma shares list on BSE and NSE today after 93.72 times subscription. Grey market signals 20% premium debut. Full details on pricing and investor response.
Sudeep Pharma IPO makes Dalal Street debut on November 28. Grey market premium hits ₹100, signaling 15% listing gain. Discover subscription details and key facts.
Bokaro police register FIR against Aryan Singh of New Sun Pharma for illegal codeine syrup trade. 32,000 bottles seized. Read the full investigation details.
Shaily Engineering and Gland Pharma positioned to benefit from India's semaglutide gold rush as patent expiry opens market for generic weight-loss drugs. Discover how these companies are preparing.
Sudeep Pharma IPO allotment finalized today after massive 93.71x subscription. GMP at ₹87 signals 14.67% listing gain. Track your allotment status now!
Sudeep Pharma IPO allotment likely on November 26. Learn how to check allotment status via BSE, NSE, registrar. Strong 93.72x subscription signals investor confidence.
Discover why current affairs knowledge is crucial for Indian students' academic performance, communication skills, and competitive exam success. Build confidence for future readiness.
Sudeep Pharma's ₹895 crore IPO witnessed massive demand, subscribed 94 times. QIB portion booked 213x. Shares may list at a 14% premium. Key details inside.
Sudeep Pharma IPO sees massive 5.09x subscription on Day 2. Grey market premium hits ₹86. Allotment scheduled for November 26. Apply before closing tomorrow!